Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology reported a strong cash position of $19.38 million for the March 2026 quarter, with more than 81% of expenditure directed to R&D and drug manufacturing, and additional funding from early option conversions extending its runway to support committed programs through 2027. During the period, the company advanced its pipeline via a new Emory University collaboration in osimertinib-resistant lung cancer, initiated patient recruitment in the Phase 1 HARNESS-1 NSCLC trial, expanded dosing in the CPACS Phase 1 trial including its first Hong Kong patient, and developed a blood-based molecular test to assess RC220’s cardioprotective effects, reinforcing its scientific profile with a selected presentation at the 2026 AACR meeting and its inaugural R&D symposium.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian clinical-stage biopharmaceutical company focused on developing novel oncology therapies, notably (E,E)-bisantrene and its lead candidate RC220. The company targets hard-to-treat cancers, including EGFR-mutated non-small cell lung cancer and anthracycline-treated solid tumours, with an emphasis on improving efficacy and cardioprotection.
Average Trading Volume: 199,628
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$499.9M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.